Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-Prognosis Advanced Lymphoid Malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Rituximab
Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions

01 Jun 2016 Trial phase changed from phase I/II to phase I
24 Sep 2012 Planned number of patients changed from 143 to 145 as reported by ClinicalTrials.gov.
10 Sep 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com